Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linifanib versus sorafenib in advanced hepatocellular carcinoma
2009-013435-38Phase 3Terminated
- Sponsor
- Abbott Laboratories
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of linifanib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Abbott Laboratories. Primary endpoint: Overall survival. Started Nov 2009; status: terminated.
02
Drugs
linifanib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2009-013435-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013435-38.